0 CHECKOUT

E7: The Outlook for Pharmaceuticals to 2012

  • ID: 550714
  • February 2012
  • Espicom Business Intelligence Ltd

The emerging E7 countries represent the best prospect for growth. The potential of these countries is huge: they have a combined population of over three billion people, and their economies are performing well. One consequence of this increasing wealth is a growing financial capacity to treat previously unmet health needs. Another is increasing incidence of 'affluence' diseases such as diabetes, as people live longer and have more sedentary lifestyles.

Executive Summary

The E7 economies represent increasing opportunities for pharmaceutical companies constrained by maturing markets in the west.

Huge potential in E7 markets

The emerging E7 countries represent the best prospect for growth. The potential of these countries is huge: they have a combined population of over three billion people, and their economies are performing well. One consequence of this increasing wealth is a growing financial capacity to treat previously unmet health needs. Another is increasing incidence of 'affluence' diseases such as diabetes, as people live longer and have more sedentary lifestyles.

HIGHLIGHTS FROM THE REGION...

BRAZIL
The government aims to encourage READ MORE >

Note: Product cover images may vary from those shown

FOR EVERY MARKET, SENT QUARTERLY

MARKET OUTLOOK
Current market size
Unique 5-Year market projections to 2012
Market outlook
Comment & rating, covering 8 key areas such as use of generic drugs, intellectual property, pricing and the health systems
Market structure
Statistical data on imports and exports
Market developments, covering recent and impending developments with respect to key issues such as regulation, health facilities, funding and
government policy
Key national data projections

FOR EVERY MARKET, SENT ANNUALLY

BACKGROUND DATA
Population data, including growth trends and age structure
Demographic indicators detailing principal causes of death and morbidity

HEALTHCARE SYSTEM
Organisation & administration
Health expenditure
- Expenditure by source of funding and type
Hospital services
- Hospital data such as beds by type, region, specialty, patient admissions and surgical procedures
Outpatient care
Medical personnel
- Data on healthcare professionals covering such areas as doctors by specialty, nursing staff and dentists

ACCESSING THE PHARMA MARKET
Regulatory environment
Distribution guide and trade fair information
Domestic production

CONTACT DETAILS
Healthcare organisations
Trade associations

Note: Product cover images may vary from those shown

- Brazil
- India
- Mexico
- Turkey
- China
- Indonesia
- Russia

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. Online access is provided for this product. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

  • Quick Help: The report will be emailed to you. Online access is provided for this product. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS

Our Clients

  • Pfizer, Inc.
  • Grünenthal GmbH
  • GlaxoSmithKline PLC
  • Abbott Laboratories Ltd.
  • Roche Diagnostics Ltd.
  • Novo Nordisk A/S